Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Holdings Lessened by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. reduced its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 10.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 384,771 shares of the medical technology company’s stock after selling 47,085 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Alphatec were worth $3,532,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. HighTower Advisors LLC boosted its holdings in shares of Alphatec by 16.2% during the third quarter. HighTower Advisors LLC now owns 52,232 shares of the medical technology company’s stock worth $290,000 after purchasing an additional 7,299 shares during the period. Stifel Financial Corp increased its stake in shares of Alphatec by 19.7% in the third quarter. Stifel Financial Corp now owns 178,702 shares of the medical technology company’s stock worth $994,000 after purchasing an additional 29,411 shares during the period. State Street Corp lifted its position in shares of Alphatec by 10.1% during the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock worth $17,453,000 after purchasing an additional 287,350 shares during the last quarter. XTX Topco Ltd bought a new stake in Alphatec during the 3rd quarter valued at approximately $69,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Alphatec in the 3rd quarter valued at approximately $147,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP David Sponsel sold 36,256 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $11.42, for a total transaction of $414,043.52. Following the completion of the sale, the executive vice president now owns 735,074 shares of the company’s stock, valued at approximately $8,394,545.08. This represents a 4.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Patrick Miles sold 6,687 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total value of $80,244.00. Following the transaction, the chief executive officer now directly owns 5,501,715 shares of the company’s stock, valued at $66,020,580. This trade represents a 0.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 278,800 shares of company stock worth $3,201,469 over the last three months. Insiders own 22.80% of the company’s stock.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $10.56 on Friday. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The business has a 50-day moving average of $10.38 and a 200-day moving average of $9.42. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -8.25 and a beta of 1.20. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $13.79.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The business had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. As a group, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

ATEC has been the subject of a number of research analyst reports. Barclays upped their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Alphatec in a research report on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Finally, Piper Sandler increased their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alphatec presently has an average rating of “Moderate Buy” and a consensus target price of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.